Citations

Showing 10 of 108104 citations.

Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta‐analysis of individualized participant data
Ørholt, Mathias , Aaberg, Frederik L., Abebe, Kiya , Roenigk, Randall K., Venzo, Alessandro, Schmidt, Grethe , Klyver, Helle, Jensen, David Hebbelstrup , Herly, Mikkel , Vester‐Glowinski, Peter, Walsh, S.

Mayo Clinic

Journal of Surgical Oncology | April 20, 2022 | Volume: 126 | Issue: 3 | Pages: 555-562

10.1002/jso.26898 | PMID 35441377 Get It

AbstractBackgroundRisk factors for local atypical fibroxanthoma (AFX) recurrence and progression to pleomorphic dermal sarcoma (PDS) have not previously been identified.ObjectiveTo identify risk factors and provide follow‐up suggestions for local AFX recurrence and progression to PDS.Methods and MaterialsA literature search was performed in the PubMed, EMBASE, and Cochrane databases. The PRISMA and MOOSE guidelines were followed. The risks of local AFX recurrence and progression to PDS were presented as Kaplan–Meier plots and risk factors were presented as hazard ratios (HRs) calculated with univariate and multivariate Cox regression.ResultsFive hundred and ninety‐eight patients with AFX from 14 studies were included. Age >74 years and male sex significantly increased the risk of local recurrence (HR: 7.31 [95% confidence interval [CI]: 1.78–30.0], p < 0.01 and HR: 2.89 [95% CI: 1.04–8.01], p < 0.05, respectively). There was no difference when comparing wide local excision and Mohs' micrographic surgery (p = 0.89). The risks of local AFX recurrence and progression to PDS after 2 years were <1%.ConclusionA more intensive follow‐up regimen could be considered in patients >74 years old and males due to the higher risk of local AFX recurrence.
A Metabolomic Severity Score for Airflow Obstruction and Emphysema
Godbole, Suneeta , Pratte, Katherine , Hill, Andrew , Hastie, Annette T. , Peters, Stephen P. , Gregory, Andrew , Ortega, Victor E. , DeMeo, Dawn L. , Bhatt, Surya P. , Wells, J. Michael , Barjaktarević, Igor , Stringer, Kathleen A. , Comellas, Alejandro P. , O’Neal, Wanda K. , Kechris, Katerina , Hill, Andrew , Gregory, Andrew , Barjaktarevic, Igor , Stringer, Kathleen A , Kechris, Katerina , O'Neal, Wanda K , Comellas, Alejandro P , Bhatt, Surya P , Wells, J Michael , Labaki, Wassim W. , Moll, Matthew , Cho, Michael H. , Bowler, Russell P.

Mayo Clinic

Metabolites | April 19, 2022 | Volume: 12 | Issue: 5 | Pages: 368

10.3390/metabo12050368 | PMID 35629872 Get It

Chronic obstructive pulmonary disease (COPD) is a disease with marked metabolic disturbance. Previous studies have shown the association between single metabolites and lung function for COPD, but whether a combination of metabolites could predict phenotype is unknown. We developed metabolomic severity scores using plasma metabolomics from the Metabolon platform from two US cohorts of ever-smokers: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) (n = 648; training/testing cohort; 72% non-Hispanic, white; average age 63 years) and the COPDGene Study (n = 1120; validation cohort; 92% non-Hispanic, white; average age 67 years). Separate adaptive LASSO (adaLASSO) models were used to model forced expiratory volume at one second (FEV1) and MESA-adjusted lung density using 762 metabolites common between studies. Metabolite coefficients selected by the adaLASSO procedure were used to create a metabolomic severity score (metSS) for each outcome. A total of 132 metabolites were selected to create a metSS for FEV1. The metSS-only models explained 64.8% and 31.7% of the variability in FEV1 in the training and validation cohorts, respectively. For MESA-adjusted lung density, 129 metabolites were selected, and metSS-only models explained 59.0% of the variability in the training cohort and 17.4% in the validation cohort. Regression models including both clinical covariates and the metSS explained more variability than either the clinical covariate or metSS-only models (53.4% vs. 46.4% and 31.6%) in the validation dataset. The metabolomic pathways for arginine biosynthesis; aminoacyl-tRNA biosynthesis; and glycine, serine, and threonine pathway were enriched by adaLASSO metabolites for FEV1. This is the first demonstration of a respiratory metabolomic severity score, which shows how a metSS can add explanation of variance to clinical predictors of FEV1 and MESA-adjusted lung density. The advantage of a comprehensive metSS is that it explains more disease than individual metabolites and can account for substantial collinearity among classes of metabolites. Future studies should be performed to determine whether metSSs are similar in younger, and more racially and ethnically diverse populations as well as whether a metabolomic severity score can predict disease development in individuals who do not yet have COPD.
Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation
Katariya, Nitin , Chascsa, David M. , Giorgakis, Emmanouil , Aqel, Bashar , Moss, Adyr A. , Usón, Pedro Luiz Serrano , Mathur, Amit K. , Lizaola-Mayo, Blanca C, Giorgakis, Emmanouil , Mathur, Amit , Uson, Pedro L S , Katariya, Nitin N , Lizaola‐Mayo, Blanca , Aqel, Bashar A. , Borad, Mitesh J.

Mayo Clinic

Cancers | April 19, 2022 | Volume: 14 | Issue: 9 | Pages: 2056

10.3390/cancers14092056 | PMID 35565184 Get It

Hepatocellular Carcinoma (HCC) is the most common liver malignancy and third leading cause of cancer death worldwide. For early- and intermediate-stage disease, liver-directed therapies for locoregional control, or down-staging prior to definitive surgical therapy with hepatic resection or liver transplantation, have been studied broadly, and are the mainstays of current treatment guidelines. As HCC incidence has continued to grow, and with more patients presenting with advanced disease, our current treatment modalities do not suffice, and better therapies are needed to improve disease-specific and overall survival. Until recently, sorafenib was the only systemic therapy utilized, and was associated with dismal results. The advent of immuno-oncology has been of significant interest, and has changed the paradigm of therapy for HCC. Lately, combination regimens including atezolizumab plus bevacizumab; durvalumab plus tremelimumab; and pembrolizumab plus Lenvatinib have shown impressive responses of between 25–35%; this is much higher than responses observed with single agents. Complete responses with checkpoint inhibitor therapy have been observed in advanced-stage HCC patients. These dramatic results have naturally led to several questions. Can or should checkpoint inhibitors, or other immunotherapy combinations, be used routinely before resection or transplant? Is there a synergistic effect of immunotherapy with locoregional therapy, and will pre-treatment increase disease-free survival after surgical intervention? Is it immunologically safe to use these therapies prior to transplantation? Much is still to be learned in terms of the dosing, timing, and overall utility of the use of immune checkpoint inhibitors for pre-transplant care and down-staging. More studies will be needed to understand the management of adverse events while maximizing the therapeutic window of these agents. In this review, we look at the current data on therapy with immune checkpoint inhibitors in advanced HCC, with a focus on pre-transplant treatment prior to liver transplant.
Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems
Madamsetty, Vijay Sagar , Mohammadinejad, Reza , Uzielienè, Ilona , Nabavi, Noushin , García-Couce, Jomarien , Tavakol, Shima , Moghassemi, Saeid , Dadashzadeh, Arezoo , Makvandi, Pooyan , Pardakhty, Abbas , Afshar, Abbas Aghaei , Seyfoddin, Ali , García-Couce, Jomarien , Tavakol, Shima , Moghassemi, Saeid , Seyfoddin, Ali , Madamsetty, Vijay S , Dehshahri, Ali

Mayo Clinic

ACS Biomaterials Science & Engineering | April 19, 2022 | Volume: 8 | Issue: 5 | Pages: 1763-1790

10.1021/acsbiomaterials.2c00026 | PMID 35439408 Get It

Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy
Khaled, Samer K. , Claes, Kathleen , Goh, Yeow Tee , Leung, Nelson , Mendrek, Włodzimierz, Nakamura, Ryotaro , Sathar, Jameela , Ng, Edmund, Nangia, Narinder , Whitaker, Steve, Rambaldi, Alessandro , Members, for the OMS721-TMA-001 Study Group, Leung, Nelson , Rambaldi, Alessandro , Kwong, Yok‐Lam , Ng, Edmund, Members, for the OMS721-TMA-001 Study Group

Mayo Clinic

Journal of Clinical Oncology | April 19, 2022 | Volume: 40 | Issue: 22 | Pages: 2447-2457

10.1200/jco.21.02389 | PMID 35439028 Get It

PURPOSE Hematopoietic stem-cell transplantation–associated thrombotic microangiopathy (HSCT-TMA) is a serious complication with significant mortality and no approved therapy. HSCT-TMA results from endothelial injury, which activates the lectin pathway of complement. Narsoplimab (OMS721), an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety and efficacy in adults with HSCT-TMA. METHODS In this single-arm open-label pivotal trial ( NCT02222545 ), patients received intravenous narsoplimab once weekly for 4-8 weeks. The primary end point (response rate) required clinical improvement in two categories: (1) laboratory TMA markers (both platelet count and lactate dehydrogenase) and (2) organ function or freedom from transfusion. Patients receiving at least one dose (full analysis set [FAS]; N = 28) were analyzed. RESULTS The response rate was 61% in the FAS population. Similar responses were observed across all patient subgroups defined by baseline features, HSCT characteristics, and HSCT complications. Improvement in organ function occurred in 74% of patients in the FAS population. One-hundred-day survival after HSCT-TMA diagnosis was 68% and 94% in FAS population and responders, respectively, whereas median overall survival was 274 days in the FAS population. Narsoplimab was well tolerated, and adverse events were typical of this population, with no apparent safety signal of concern. CONCLUSION In this study, narsoplimab treatment was safe, significantly improved laboratory TMA markers, and resulted in clinical response and favorable overall survival.
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
Villa, Diego , Hoster, Eva , Klapper, Wolfram , Szymczyk, Michał, Bosly, André, Unterhalt, Michael, Rimsza, Lisa M. , Ramsower, Colleen , Freeman, Ciara L. , Gerrie, Alina S. , Dreyling, Martin , Klapper, Wolfram , Ramsower, Colleen A, Scott, David W , Gerrie, Alina S , Savage, Kerry J , Dreyling, Martin , Rimsza, Lisa M , Hoster, Eva , Hermine, Olivier , Scott, David W. , Savage, Kerry J. , Sehn, Laurie H.

Mayo Clinic

Blood Advances | April 19, 2022 | Volume: 6 | Issue: 18 | Pages: 5285-5294

10.1182/bloodadvances.2022007371 | PMID 35439293 Get It

Abstract The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, cisplatin) in transplant-eligible patients with mantle cell lymphoma (MCL). A population-based cohort of 97 patients aged 18 to 65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared with the cohort of 232 patients with MCL randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial. The primary endpoint was the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid/ pleomorphic morphology. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR, 0.87; 95% confidence interval [CI], 0.53-1.41; P = .56) or adjusted (HR, 0.79; 95% CI, 0.45-1.37; P = .40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of 2 independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP/R-DHAP with ASCT.
Left Atrial Reservoir Strain: A Savior to Diastolic Function Assessment in Hypertrophic Cardiomyopathy?
Oh, Jae K., Miranda, William R. , Miranda, William R , Oh, Jae K.

Mayo Clinic

Circulation: Cardiovascular Imaging | April 19, 2022 | Volume: 15 | Issue: 4 | Pages: No page available

10.1161/circimaging.122.014148 | PMID 35439040 Get It

Bench valvular surgery in donor's hearts before transplantation: Choice versus necessity
Ahmed, Magdy M. El‐Sayed , Pham, Anthony , Sareyyüpoğlu, Başar , Pham, Si M. , Pham, Si , Pham, Anthony

Mayo Clinic

Journal of Cardiac Surgery | April 19, 2022 | Volume: 37 | Issue: 7 | Pages: 2209-2211

10.1111/jocs.16533 | PMID 35438821 Get It

Microvascular remodeling and altered angiogenic signaling in human kidneys distal to occlusive atherosclerotic renal artery stenosis
Klomjit, Nattawat , Zhu, Xiangyang , Eirin, Alfonso , Conley, Sabena M., Ferguson, Christopher M. , Jordan, Kyra L., Saadiq, Ishran M. , Grande, Joseph P. , Textor, Stephen C., Lerman, Lilach O. , Pawar, Aditya S. , Kim, Seo Rin , Lerman, Amir , Lerman, Lilach O , Eirin, Alfonso , Klomjit, Nattawat , Puranik, Amrutesh S. , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Nephrology Dialysis Transplantation | April 19, 2022 | Volume: 37 | Issue: 10 | Pages: 1844-1856

10.1093/ndt/gfac156 | PMID 35451482 Get It

ABSTRACT Background Renal artery stenosis (RAS) is an important cause of chronic kidney disease and secondary hypertension. In animal models, renal ischemia leads to downregulation of growth factor expression and loss of intrarenal microcirculation. However, little is known about the sequelae of large-vessel occlusive disease on the microcirculation within human kidneys. Method This study included five patients who underwent nephrectomy due to renovascular occlusion and seven nonstenotic discarded donor kidneys (four deceased donors). Micro-computed tomography was performed to assess microvascular spatial densities and tortuosity, an index of microvascular immaturity. Renal protein expression, gene expression and histology were studied in vitro using immunoblotting, polymerase chain reaction and staining. Results RAS demonstrated a loss of medium-sized vessels (0.2–0.3 mm) compared with donor kidneys (P = 0.037) and increased microvascular tortuosity. RAS kidneys had greater protein expression of angiopoietin-1, hypoxia-inducible factor-1α and thrombospondin-1 but lower protein expression of vascular endothelial growth factor (VEGF) than donor kidneys. Renal fibrosis, loss of peritubular capillaries (PTCs) and pericyte detachment were greater in RAS, yet they had more newly formed PTCs than donor kidneys. Therefore, our study quantified significant microvascular remodeling in the poststenotic human kidney. RAS induced renal microvascular loss, vascular remodeling and fibrosis. Despite downregulated VEGF, stenotic kidneys upregulated compensatory angiogenic pathways related to angiopoietin-1. Conclusions These observations underscore the nature of human RAS as a microvascular disease distal to main vessel stenosis and support therapeutic strategies directly targeting the poststenotic kidney microcirculation in patients with RAS.
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
Samson, Adel , West, Emma J. , Carmichael, Jonathan , Scott, Karen J. , Turnbull, Samantha , Kuszlewicz, Bethany, Dave, Rajiv , Peckham-Cooper, Adam , Tidswell, Emma, Kingston, Jennifer , Johnpulle, Michelle, Jennings, Victoria A. , Stojkowitz, Nicolas, Lusky, Monika, Prasad, Rajendra , Toogood, Giles J. , Bell, John C. , Twelves, Chris , Harrington, Kevin J. , Vile, Richard G. , Pandha, Hardev , Errington‐Mais, Fiona , Ralph, Christy , Newton, Darren , Anthoney, Alan , Melcher, Alan , Collinson, Fiona , Dave, Rajiv V , Bendjama, Kaidre , Bell, John , Twelves, Christopher , Errington-Mais, Fiona , Ralph, Christy , Newton, Darren J , Collinson, Fiona , Melcher, Alan A , Harrington, Kevin , Silva, Bárbara da , Auer, Rebecca

Mayo Clinic

Cancer Immunology Research | April 19, 2022 | Volume: 10 | Issue: 6 | Pages: 745-756

10.1158/2326-6066.cir-21-0171 | PMID 35439304 Get It

Abstract Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials. We report the results of a single-center, nonrandomized biological end point study (trial registration: EudraCT number 2012-000704-15), which builds on the success of the presurgical intravenous delivery of oncolytic viruses to tumors. Nine patients with either colorectal cancer liver metastases or metastatic melanoma were treated with a single intravenous infusion of Pexa-Vec ahead of planned surgical resection of the metastases. Grade 3 and 4 Pexa-Vec–associated side effects were lymphopaenia and neutropaenia. Pexa-Vec was peripherally carried in plasma and was not associated with peripheral blood mononuclear cells. Upon surgical resection, Pexa-Vec was found in the majority of analyzed tumors. Pexa-Vec therapy associated with IFNα secretion, chemokine induction, and resulted in transient innate and long-lived adaptive anticancer immunity. In the 2 patients with significant and complete tumor necrosis, a reduction in the peripheral T-cell receptor diversity was observed at the time of surgery. These results support the development of presurgical oncolytic vaccinia virus-based therapies to stimulate anticancer immunity and increase the chances to cure patients with cancer.